Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

The role of premorbid IQ and age of onset as useful predictors of clinical, functional outcomes, and recovery of individuals with a first episode of psychosis

  • Molina-García, Mariola
  • Fraguas, David
  • Rey-Mejías, Ángel del
  • Mezquida, Gisela
  • Sánchez Torres, Ana María
  • Amoretti, Silvia
  • Lobo, Antonio
  • González Pinto, Ana
  • Andreu-Bernabeu, Álvaro
  • Corripio, Iluminada
  • Vieta, Eduard
  • Baeza, Inmaculada
  • Mané, Anna
  • Cuesta, Manuel J.
  • Serna, Elena de la
  • Payá, Beatriz
  • Zorrilla, Iñaki
  • Arango, Celso
  • Bernardo, Miguel
  • Rapado-Castro, Marta
  • Parellada, Mara
  • PEPs Group
Background: premorbid IQ (pIQ) and age of onset are predictors of clinical severity and long-term functioning after a first episode of psychosis. However, the additive influence of these variables on clinical, functional, and recovery rates outcomes is largely unknown. Methods: we characterized 255 individuals who have experienced a first episode of psychosis in four a priori defined subgroups based on pIQ (low pIQ < 85; average pIQ ≥ 85) and age of onset (early onset < 18 years; adult onset ≥ 18 years). We conducted clinical and functional assessments at baseline and at two-year follow-up. We calculated symptom remission and recovery rates using the Positive and Negative Symptoms of Schizophrenia Schedule (PANSS) and the Global Assessment Functioning (GAF or Children-GAF). We examined clinical and functional changes with pair-wise comparisons and two-way mixed ANOVA. We built hierarchical lineal and logistic regression models to estimate the predictive value of the independent variables over functioning or recovery rates. Results: early-onset patients had more severe positive symptoms and poorer functioning than adult-onset patients. At two-year follow-up, only early-onset with low pIQ and adult-onset with average pIQ subgroups differed consistently, with the former having more negative symptoms (d = 0.59), poorer functioning (d = 0.82), lower remission (61% vs. 81.1%), and clinical recovery (34.1% vs. 62.2%). Conclusions: early-onset individuals with low pIQ may present persistent negative symptoms, lower functioning, and less recovery likelihood at two-year follow-up. Intensive cognitive and functional programs for these individuals merit testing to improve long-term recovery rates in this subgroup., This work was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III, PI02/1248, PI03032, PI05/0678, PI08/0208 PI09/01442, PI11/00325, PI12/1303, PI14/00612, PI15/00723, PI17/009977, PI18/00753 cofinanced by ERDF Funds from the European Commission, 'A way of making Europe', CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2). The CERCA Program/Generalitat de Catalunya And Secretaria d'Universitats i Recerca del Departament d'Economia I Coneixement (2017SGR1355). Departament de Salut de la Generalitat de Catalunya, en la convocatoria corresponent a l'any 2017 de concessió de subvencions del Pla Estratègic de Recerca i Innovació en Salut (PERIS) 2016-2020, modalitat Projectes de recerca orientats a l'atenció primària, amb el codi d'expedient SLT006/17/00345. European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTi-MISE), FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Opposite cannabis-cognition associations in psychotic patients depending on family history

  • González Pinto, Ana
  • González-Ortega, Itxaso
  • Alberich, Susana
  • Ruiz de Azúa, Sonia
  • Bernardo, Miguel
  • Bioque, Miquel
  • Cabrera, Bibiana
  • Corripio, Iluminada
  • Arango, Celso
  • Lobo, Antonio
  • Sánchez Torres, Ana María
  • Cuesta, Manuel J.
  • PEPs Group
The objective of this study is to investigate cognitive performance in a first-episode psychosis sample, when stratifying the interaction by cannabis use and familial or non-familial psychosis. Hierarchical-regression models were used to analyse this association in a sample of 268 first-episode psychosis patients and 237 controls. We found that cannabis use was associated with worse working memory, regardless of family history. However, cannabis use was clearly associated with worse cognitive performance in patients with no family history of psychosis, in cognitive domains including verbal memory, executive function and global cognitive index, whereas cannabis users with a family history of psychosis performed better in these domains. The main finding of the study is that there is an interaction between cannabis use and a family history of psychosis in the areas of verbal memory, executive function and global cognition: that is, cannabis use is associated with a better performance in patients with a family history of psychosis and a worse performance in those with no family history of psychosis. In order to confirm this hypothesis, future research should explore the actual expression of the endocannabinoid system in patients with and without a family history of psychosis., The Spanish Ministry of Economy and Competitiveness (Ref. ISCIII 2009-2011:PI 080208), the Instituto de Salud Carlos III-European Fund for Regional Development (PI10/01430, PI10/01746, PI11/01977, PI11/02708, 2011/1064, PI12/02077, PI13/02252, PI13/00451 and PI14/01900, PI11/02831), the Centre for Biomedical Research in the Mental Health Network (CIBERSAM), the Health Department of the Government of Navarre (11/101 and 87/2014), the Government of Catalonia, Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement (2014SGR441), the Contract FI-DGR-2013 from the Agència de Gestió d'Ajuts Universitaris i de Recerca, AGAUR (2015 FI_B2 00100 to GM), the Esther Koplowitz Centre (Barcelona), local grants from the Department of Education, Linguistic Policy and Culture of the Basque Country Government, the Basque Foundation for Health Innovation and Research (BIOEF), Madrid Regional Government (S2010/BMD-2422 AGES), European Union Structural Funds and European Union Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTiMISE), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7-HEALTH-2013-2.2.1-2-602478 (Project METSY); Alicia Koplowitz Foundation, Mutua Madrileña Foundation and the University of the Basque Country (GIC10/80, GIC12/84). The psychiatric research department at Araba University Hospital is supported by the Stanley Research Foundation (03-RC-003).
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Opposite cannabis-cognition associations in psychotic patients depending on family history

  • González-Pinto, Ana
  • González Ortega, Itxaso
  • Alberich, Susana
  • Ruiz de Azúa, Sonia
  • Bernardo Arroyo, Miquel
  • Bioque Alcázar, Miquel
  • Cabrera, Bibiana
  • Corripio, Iluminada
  • Arango, Celso
  • Lobo, Antonio
  • Sánchez-Torres, Ana M.
  • Cuesta, Manuel J.
  • PEPs Group
The objective of this study is to investigate cognitive performance in a first-episode psycho- sis sample, when stratifying the interaction by cannabis use and familial or non-familial psy- chosis. Hierarchical-regression models were used to analyse this association in a sample of 268 first-episode psychosis patients and 237 controls. We found that cannabis use was associated with worse working memory, regardless of family history. However, cannabis use was clearly associated with worse cognitive performance in patients with no family his- tory of psychosis, in cognitive domains including verbal memory, executive function and global cognitive index, whereas cannabis users with a family history of psychosis performed better in these domains. The main finding of the study is that there is an interaction between cannabis use and a family history of psychosis in the areas of verbal memory, executive function and global cognition: that is, cannabis use is associated with a better performance in patients with a family history of psychosis and a worse performance in those with no fam- ily history of psychosis. In order to confirm this hypothesis, future research should explore the actual expression of the endocannabinoid system in patients with and without a family history of psychosis
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Altered structural brain asymmetry in autism spectrum disorder in a study of 54 datasets

  • Postema, Merel C.
  • van Rooij, Daan
  • Anagnostou, Evdokia
  • Arango, Celso
  • Auzias, Guillaume
  • Behrmann, Marlene
  • Filho, Geraldo Busatto
  • Calderoni, Sara
  • Calvo Escalona, Rosa
  • Daly, Eileen
  • Deruelle, Christine
  • Di Martino, Adriana
  • Dinstein, Illan
  • Duran, Fabio Luis S.
  • Durston, Sarah
  • Ecker, Christine
  • Ehrlich, Stefan
  • Fair, Damien
  • Fedor, Jennifer
  • Feng, Xin
  • FitzGerald, Jackie
  • Floris, Dorothea L.
  • Freitag, Christine M.
  • Gallagher, Louise
  • Glahn, David C.
  • Gori, Ilaria
  • Haar, Shlomi
  • Hoekstra, Liesbeth
  • Jahanshad, Neda
  • Jalbrzikowski, Maria
  • Janssen, Joost
  • King, Joseph A.
  • Kong, Xiang-Zhen
  • Lázaro García, Luisa
  • Lerch, Jason P.
  • Luna, Beatriz
  • Martinho, Mauricio M.
  • McGrath, Jane
  • Medland, Sarah E.
  • Muratori, Filippo
Altered structural brain asymmetry in autism spectrum disorder (ASD) has been reported. However, findings have been inconsistent, likely due to limited sample sizes. Here we investigated 1,774 individuals with ASD and 1,809 controls, from 54 independent data sets of the ENIGMA consortium. ASD was significantly associated with alterations of cortical thickness asymmetry in mostly medial frontal, orbitofrontal, cingulate and inferior temporal areas, and also with asymmetry of orbitofrontal surface area. These differences generally involved reduced asymmetry in individuals with ASD compared to controls. Furthermore, putamen volume asymmetry was significantly increased in ASD. The largest case-control effect size was Cohen's d = -0.13, for asymmetry of superior frontal cortical thickness. Most effects did not depend on age, sex, IQ, severity or medication use. Altered lateralized neurodevelopment may therefore be a feature of ASD, affecting widespread brain regions with diverse functions. Large-scale analysis was necessary to quantify subtle alterations of brain structural asymmetry in ASD.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

In vivo white matter microstructure in adolescents with early-onset psychosis: a multi-site mega-analysis

  • Barth, Claudia
  • Crespo-Facorro, Benedicto
  • Tordesillas-Gutiérrez, Diana
et al., Emerging evidence suggests brain white matter alterations in adolescents with early-onset psychosis (EOP; age of onset <18 years). However, as neuroimaging methods vary and sample sizes are modest, results remain inconclusive. Using harmonized data processing protocols and a mega-analytic approach, we compared white matter microstructure in EOP and healthy controls using diffusion tensor imaging (DTI). Our sample included 321 adolescents with EOP (median age = 16.6 years, interquartile range (IQR) = 2.14, 46.4% females) and 265 adolescent healthy controls (median age = 16.2 years, IQR = 2.43, 57.7% females) pooled from nine sites. All sites extracted mean fractional anisotropy (FA), mean diffusivity (MD), radial diffusivity (RD), and axial diffusivity (AD) for 25 white matter regions of interest per participant. ComBat harmonization was performed for all DTI measures to adjust for scanner differences. Multiple linear regression models were fitted to investigate case-control differences and associations with clinical variables in regional DTI measures. We found widespread lower FA in EOP compared to healthy controls, with the largest effect sizes in the superior longitudinal fasciculus (Cohen’s d = 0.37), posterior corona radiata (d = 0.32), and superior fronto‐occipital fasciculus (d = 0.31). We also found widespread higher RD and more localized higher MD and AD. We detected significant effects of diagnostic subgroup, sex, and duration of illness, but not medication status. Using the largest EOP DTI sample to date, our findings suggest a profile of widespread white matter microstructure alterations in adolescents with EOP, most prominently in male individuals with early-onset schizophrenia and individuals with a shorter duration of illness., ENIGMA Core: U.S. National Institutes of Health grants, R01 EB015611, U54 EB020403, R01 MH116147, R01 MH117601, R01 MH121246, S10 OD023696. YTOP: The Research Council of Norway (223273, 2137000, 250358, 288083); South-Eastern Norway Regional Health Authority (2017112, 2022080); KG Jebsen Stiftelsen (SKGJ-MED-008). MADRID: Celso Arango has received funding from CIBERSAM: Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, co-financed by ERDF Funds from the European Commission, “A way of making Europe”; CIBERSAM; Instituto de Investigación Sanitaria Gregorio Marañón; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2, Youth Employment Operational Program and Youth Employment Initiative); European Social Fund and EU Structural Funds; EU Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909, FP7-HEALTH-2009-2.2.1-3-242114, FP7-HEALTH-2013-2.2.1-2-602478, and FP7-HEALTH-2013-2.2.1-2-603196; EU H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso, Fundación Alicia Koplowitz and Fundación Mutua Madrileña. Covadonga M. Díaz-Cenaj has received grant support from Instituto de Salud Carlos III (PI17/00481, PI20/00721, JR19/00024). FEMS: This project was supported by an unrestricted grant from AstraZeneca. Michael Berk is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (1059660 and APP1156072). SCAPS: The Swedish Research Council (521-2014-3487, 2017-00949); FORMAS (259-2012-31). OXFORD: MRC G0500092. PAFIP: This study was supported by grants from Carlos III Health Institute (IPI17/00402, PI17/01056, PI14/00639 and PI14/00918) cofunded by The European Union through FEDER funds and Fundación Instituto de Investigación Marqués de Valdecilla (NCT0235832 and NCT02534363). No pharmaceutical company has financially supported the study. BARCELONA: Inmaculada Baeza has received research funds from the Spanish Ministry of Health, Instituto de Salud Carlos II, supported by ERDF Funds from the European Comission (PI18/0242 and PI21/0391), “Otra manera de hacer Europa”, and Fundación Alcia Koplowitz. Elena de la Serna has received grant support from Instituto de Salud Carlos III (PI20/00654). Gisela Sugranyes has received research funds from Instituto de Salud Carlos III (PI1800976 and PI2100330), the Alicia Koplowitz Foundation (AKOPLOWITZ20_004), Ajut a la Recerca Pons Bartran (FCRB_PB1_2018) and a Brain and Behaviour Research Foundation NARSAD 2017 Young Investigator Grant (26731). UCLA: NIMH grants U01MH081902, P50MH066286., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Opposite cannabis-cognition associations in psychotic patients depending on family history

  • González-Pinto, A.
  • González-Ortega, I.
  • Alberich, S.
  • De Azúa, S.R.
  • Bernardo, M.
  • Bioque, M.
  • Cabrera, B.
  • Corripio, I.
  • Arango, C.
  • Lobo, A.
  • Sánchez-Torres, A.M.
  • Cuesta, M.J.
  • Ugarte, A.
  • Fernández, M.
  • Mezquida, G.
  • Meseguer, A.
  • Vieta, E.
  • Torrent, C.
  • Contreras, F.
  • Albacete, A.
  • Alonso-Solís, A.
  • Rabella, M.
  • Moreno-Izco, L.
  • Usall, J.
  • Butjosa, A.
  • Ibáñez, Á.
  • Bobes, J.
  • Al-Halabí, S.
  • Zapata-Usábel, M.T.
  • Laporta-Herrero, I.
  • Balanzá-Martínez, V.
  • Bergé, D.
  • Mané, A.
  • Rodriguez-Jimenez, R.
  • Morales-Muñoz, I.
  • Gutierrez, M.
  • Zabala, A.
  • Sarró, S.
  • Landin-Romero, R.
  • Serna, De La
  • Baeza, I.
  • Parellada, M.
  • Espliego, A.
  • Juan, J.S.
  • Aguilar, E.
The objective of this study is to investigate cognitive performance in a first-episode psychosis sample, when stratifying the interaction by cannabis use and familial or non-familial psychosis. Hierarchical-regression models were used to analyse this association in a sample of 268 first-episode psychosis patients and 237 controls. We found that cannabis use was associated with worse working memory, regardless of family history. However, cannabis use was clearly associated with worse cognitive performance in patients with no family history of psychosis, in cognitive domains including verbal memory, executive function and global cognitive index, whereas cannabis users with a family history of psychosis performed better in these domains. The main finding of the study is that there is an interaction between cannabis use and a family history of psychosis in the areas of verbal memory, executive function and global cognition: that is, cannabis use is associated with a better performance in patients with a family history of psychosis and a worse performance in those with no family history of psychosis. In order to confirm this hypothesis, future research should explore the actual expression of the endocannabinoid system in patients with and without a family history of psychosis.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Altered structural brain asymmetry in autism spectrum disorder in a study of 54 datasets

  • Postema, Merel C.
  • van Rooij, Daan
  • Anagnostou, Evdokia
  • Arango, Celso
  • Auzias, Guillaume
  • Behrmann, Marlene
  • Filho, Geraldo Busatto
  • Calderoni, Sara
  • Calvo Escalona, Rosa
  • Daly, Eileen
  • Deruelle, Christine
  • Di Martino, Adriana
  • Dinstein, Illan
  • Duran, Fabio Luis S.
  • Durston, Sarah
  • Ecker, Christine
  • Ehrlich, Stefan
  • Fair, Damien
  • Fedor, Jennifer
  • Feng, Xin
  • FitzGerald, Jackie
  • Floris, Dorothea L.
  • Freitag, Christine M.
  • Gallagher, Louise
  • Glahn, David C.
  • Gori, Ilaria
  • Haar, Shlomi
  • Hoekstra, Liesbeth
  • Jahanshad, Neda
  • Jalbrzikowski, Maria
  • Janssen, Joost
  • King, Joseph A.
  • Kong, Xiang-Zhen
  • Lázaro García, Luisa
  • Lerch, Jason P.
  • Luna, Beatriz
  • Martinho, Mauricio M.
  • McGrath, Jane
  • Medland, Sarah E.
  • Muratori, Filippo
Altered structural brain asymmetry in autism spectrum disorder (ASD) has been reported. However, findings have been inconsistent, likely due to limited sample sizes. Here we investigated 1,774 individuals with ASD and 1,809 controls, from 54 independent data sets of the ENIGMA consortium. ASD was significantly associated with alterations of cortical thickness asymmetry in mostly medial frontal, orbitofrontal, cingulate and inferior temporal areas, and also with asymmetry of orbitofrontal surface area. These differences generally involved reduced asymmetry in individuals with ASD compared to controls. Furthermore, putamen volume asymmetry was significantly increased in ASD. The largest case-control effect size was Cohen's d = -0.13, for asymmetry of superior frontal cortical thickness. Most effects did not depend on age, sex, IQ, severity or medication use. Altered lateralized neurodevelopment may therefore be a feature of ASD, affecting widespread brain regions with diverse functions. Large-scale analysis was necessary to quantify subtle alterations of brain structural asymmetry in ASD.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Opposite cannabis-cognition associations in psychotic patients depending on family history

  • González-Pinto, Ana
  • González Ortega, Itxaso
  • Alberich, Susana
  • Ruiz de Azúa, Sonia
  • Bernardo Arroyo, Miquel
  • Bioque Alcázar, Miquel
  • Cabrera, Bibiana
  • Corripio, Iluminada
  • Arango, Celso
  • Lobo, Antonio
  • Sánchez-Torres, Ana M.
  • Cuesta, Manuel J.
  • PEPs Group
The objective of this study is to investigate cognitive performance in a first-episode psycho- sis sample, when stratifying the interaction by cannabis use and familial or non-familial psy- chosis. Hierarchical-regression models were used to analyse this association in a sample of 268 first-episode psychosis patients and 237 controls. We found that cannabis use was associated with worse working memory, regardless of family history. However, cannabis use was clearly associated with worse cognitive performance in patients with no family his- tory of psychosis, in cognitive domains including verbal memory, executive function and global cognitive index, whereas cannabis users with a family history of psychosis performed better in these domains. The main finding of the study is that there is an interaction between cannabis use and a family history of psychosis in the areas of verbal memory, executive function and global cognition: that is, cannabis use is associated with a better performance in patients with a family history of psychosis and a worse performance in those with no fam- ily history of psychosis. In order to confirm this hypothesis, future research should explore the actual expression of the endocannabinoid system in patients with and without a family history of psychosis
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History

  • González-Pinto, Ana|||0000-0002-2568-5179
  • González-Ortega, Itxaso|||0000-0001-7074-4353
  • Alberich, Susana|||0000-0002-4945-3428
  • Ruiz de Azúa, Sonia
  • Bernardo, Miquel|||0000-0001-8748-6717
  • Bioque, Miquel|||0000-0001-6887-7149
  • Cabrera, Bibiana|||0000-0002-7749-5449
  • Corripio, Iluminada|||0000-0003-2562-711X
  • Arango, Celso|||0000-0003-3382-4754
  • Lobo, Antonio|||0000-0002-9098-655X
  • Sánchez Torres, Ana Maria|||0000-0002-9505-2406
  • Cuesta, Manuel J.|||0000-0003-0250-5718
The objective of this study is to investigate cognitive performance in a first-episode psychosis sample, when stratifying the interaction by cannabis use and familial or non-familial psychosis. Hierarchical-regression models were used to analyse this association in a sample of 268 first-episode psychosis patients and 237 controls. We found that cannabis use was associated with worse working memory, regardless of family history. However, cannabis use was clearly associated with worse cognitive performance in patients with no family history of psychosis, in cognitive domains including verbal memory, executive function and global cognitive index, whereas cannabis users with a family history of psychosis performed better in these domains. The main finding of the study is that there is an interaction between cannabis use and a family history of psychosis in the areas of verbal memory, executive function and global cognition: that is, cannabis use is associated with a better performance in patients with a family history of psychosis and a worse performance in those with no family history of psychosis. In order to confirm this hypothesis, future research should explore the actual expression of the endocannabinoid system in patients with and without a family history of psychosis.
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Searching for bridges between psychopathology and real-world functioning in first-episode psychosis: a network analysis from the OPTiMiSE trial

  • Dal Santo, Francesco|||0000-0002-9879-6443
  • Fonseca Pedrero, Eduardo|||0000-0001-7453-5225
  • García-Portilla González, María Paz|||0000-0003-3643-1622
  • González Blanco, Leticia|||0000-0001-6238-4773
  • Saiz Martínez, Pilar Alejandra
  • Galderisi, S.
  • Giordano, Giulia María
  • Bobes, Julio|||0000-0003-2187-4033
This study was funded by the European Commission Seventh Framework Programme (HEALTH-F2-2010-242114)
RUO. Repositorio Institucional de la Universidad de Oviedo
Publicación Artículo científico (JournalArticle)

Optimizing subjective wellbeing with amisulpride in first episode schizophrenia or related disorders

  • de Haan, Lieuwe
  • Van Tricht, Mirjam
  • Van Dijk, Floor
  • Arango, Celso
  • Díaz Caneja, Covadonga M.
  • Bobes, Julio|||0000-0003-2187-4033
  • García Álvarez, Leticia
  • Leucht, Stefan
European Commission within the 7th Program [HEALTH-F2-2010-242114]; Covadonga M. Díaz-Caneja holds grant from Instituto de Salud Carlos III (PI17/00481, PI20/00721, JR19/00024)